120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
奥希替尼联合铂类化疗治疗 EGFR 突变非小细胞肺癌的临床结局：一项回顾性研究
Received 22 September 2025
Accepted for publication 7 January 2026
Published 3 February 2026 Volume 2026:19 566952
DOI https://doi.org/10.2147/PGPM.S566952
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Martin H Bluth
Ruixue Han,1 Xin Yu2
1Department of Oncology, The Second People’s Hospital of Yuhuan City, Yuhuan, Zhejiang, 317605, People’s Republic of China; 2Department of Respiratory Medicine, Zhuji Hospital of Traditional Chinese Medicine, Zhuji, Zhejiang, 311800, People’s Republic of China
Correspondence: Xin Yu, Email hzn1278@yeah.net
Objective: To assess the clinical outcomes of osimertinib combined with platinum-based chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) and to describe associated changes in angiogenesis-related and tumor marker levels.
Methods: A retrospective analysis was performed on 112 NSCLC patients with EGFR-sensitive mutations treated from June 2018 to October 2020. Patients received either pemetrexed plus cisplatin (control group, n=56) or the same regimen with osimertinib (experimental group, n=56). Evaluation parameters included objective response rate (ORR), disease control rate (DCR), vascular endothelial growth factor (VEGF), angiopoietin-2 (Ang-2), carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA21-1), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events.
Results: ORR was comparable between groups (P> 0.05), whereas the experimental group showed a significantly higher DCR (P< 0.05). Post-treatment VEGF, Ang-2, CEA, and CYFRA21-1 levels decreased in both groups, with greater reductions observed in the experimental group (P< 0.05). Median follow-up was 18.8 months. The experimental group demonstrated longer median PFS (15.7 vs 10.6 months, χ2=18.337, P< 0.001) and OS (24.6 vs 17.5 months, χ2=24.679, P< 0.001). The incidence of adverse reactions did not differ significantly between groups (P> 0.05).
Conclusion: In this retrospective cohort, the addition of osimertinib to platinum-based chemotherapy was associated with improved disease control and prolonged survival, along with greater reductions in angiogenesis-related and tumor marker levels, without increasing treatment-related toxicity.
Keywords: EGFR mutation, NSCLC, chemotherapy, osimertinib, clinical outcomes, angiogenesis
1Department of Oncology, The Second People’s Hospital of Yuhuan City, Yuhuan, Zhejiang, 317605, People’s Republic of China; 2Department of Respiratory Medicine, Zhuji Hospital of Traditional Chinese Medicine, Zhuji, Zhejiang, 311800, People’s Republic of China
Correspondence: Xin Yu, Email hzn1278@yeah.net
Objective: To assess the clinical outcomes of osimertinib combined with platinum-based chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) and to describe associated changes in angiogenesis-related and tumor marker levels.
Methods: A retrospective analysis was performed on 112 NSCLC patients with EGFR-sensitive mutations treated from June 2018 to October 2020. Patients received either pemetrexed plus cisplatin (control group, n=56) or the same regimen with osimertinib (experimental group, n=56). Evaluation parameters included objective response rate (ORR), disease control rate (DCR), vascular endothelial growth factor (VEGF), angiopoietin-2 (Ang-2), carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA21-1), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events.
Results: ORR was comparable between groups (P> 0.05), whereas the experimental group showed a significantly higher DCR (P< 0.05). Post-treatment VEGF, Ang-2, CEA, and CYFRA21-1 levels decreased in both groups, with greater reductions observed in the experimental group (P< 0.05). Median follow-up was 18.8 months. The experimental group demonstrated longer median PFS (15.7 vs 10.6 months, χ2=18.337, P< 0.001) and OS (24.6 vs 17.5 months, χ2=24.679, P< 0.001). The incidence of adverse reactions did not differ significantly between groups (P> 0.05).
Conclusion: In this retrospective cohort, the addition of osimertinib to platinum-based chemotherapy was associated with improved disease control and prolonged survival, along with greater reductions in angiogenesis-related and tumor marker levels, without increasing treatment-related toxicity.
Keywords: EGFR mutation, NSCLC, chemotherapy, osimertinib, clinical outcomes, angiogenesis